Liposarcoma (advanced unresectable dedifferentiated liposarcoma) | SEAL
Indication: Liposarcoma
Title: SEAL: Selinexor in Advanced Liposarcoma
Drug: selinexor
SEAL is a Phase 3 randomized, multicenter, double-blind, placebo-controlled study evaluating selinexor in patients with advanced unresectable dedifferentiated liposarcoma
Please visit clinicaltrials.gov for more information about this study
This trial is for selinexor.
Phase I | Phase II | Phase III |
---|---|---|
Phase I | Phase II | Phase III |